Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate

M. N. Zamotaeva; V. I. Inchina; V. V. Konorev; Yu. V. Kuznetsov; N. D. Kuz’michev

doi:10.1007/s10517-018-4166-y

Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate

Autores: Zamotaeva M.¹, Inchina V.¹, Konorev V.¹, Kuznetsov Y.², Kuz’michev N.¹
Afiliações:
1. N. P. Ogarev Mordovian National Research State University
2. N. M. Emanuel Institute of Biochemical Physics
Edição: Volume 165, Nº 3 (2018)
Páginas: 344-346
Seção: Article
URL: https://journals.rcsi.science/0007-4888/article/view/240286
DOI: https://doi.org/10.1007/s10517-018-4166-y
ID: 240286

Citar

Texto integral

Acesso aberto
Acesso é fechado

Acesso está concedido
Acesso é fechado

Somente assinantes

Resumo
Sobre autores
Bibliografia
Estatísticas

Resumo

The possibility of correction of morphological changes in the myocardium and biochemical parameters of the blood with 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg was studied in the model of doxorubicin-induced chronic heart failure in rats. It was found that 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg produced less pronounced cardio-protective effect in experimental chronic heart failure than 3-hydroxypyridine succinate.